Familial chylomicronemia syndrome, or FCS, is a rare genetic disease, characterized by extremely high triglyceride levels, typically over 880 mg/dL. Such elevated triglyceride levels can lead to various serious signs and symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues. Currently, there are FDA-approved therapeutic options to treat FCS.
The company we are profiling today is Arrowhead Pharmaceuticals Inc. (ARWR), which is developing a drug for the treatment of patients with FCS.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com